

**UNITED STATES PATENT AND TRADEMARK OFFICE**

---

**BEFORE THE PATENT TRIAL AND APPEAL BOARD**

---

**SAMSUNG BIOEPIS CO., LTD.**  
Petitioner,

v.

**REGENERON PHARMACEUTICALS, INC.**  
Patent Owner.

Patent No. 11,253,572

---

*Inter Partes* Review No. IPR2023-00884

---

**PATENT OWNER'S MOTION FOR *PRO HAC VICE* ADMISSION OF  
KIRA A. DAVIS UNDER 37 C.F.R. § 42.10(c)**

**I. Relief Requested**

Pursuant to 37 C.F.R. § 42.10, Patent Owner Regeneron Pharmaceuticals, Inc., requests that the Board admit Kira A. Davis *pro hac vice* in this proceeding.

**II. Statement of Facts Showing Good Cause for the Board to Recognize Counsel *Pro Hac Vice* During the Proceeding**

In accordance with 37 C.F.R. § 42.10(c), the Board may recognize counsel *pro hac vice* during a proceeding, subject to the conditions set forth therein, and any others that the Board may impose. Patent Owner sets forth these facts in support of this motion:

1. The undersigned contacted counsel for Petitioner (Quinn Emanuel Urquhart & Sullivan LLP), who indicated that Petitioner did not plan to oppose Ms. Davis's admission *pro hac vice*.
2. Lead counsel for Patent Owner, Regeneron Pharmaceuticals, Inc., Adam Brausa, and Backup counsel, Rebecca Weires are registered practitioners.
3. Kira A. Davis is an experienced litigator and has established familiarity with the subject matter at issue in this proceeding. Accompanying this motion is **Exhibit 2060**, the Declaration of Kira A. Davis in Support of this Motion for Admission *Pro Hac Vice* ("Davis Decl."). In her declaration, Ms. Davis attests, among other things, that she is a member in good standing of the bars of the states of California and New York. Davis Decl. ¶¶ 1-2. Ms. Davis has never been subject to suspensions or disbarments from practice, nor had applications for

admission to practice denied, nor been subject to any sanctions or contempt citations by any court or administrative body. *Id.* ¶¶ 3-5.

4. Ms. Davis has approximately 12 years of experience litigating patent cases involving biotechnology. Davis Decl. ¶ 9. As is relevant to this matter, during the past 12 years, Ms. Davis has litigated a number of cases involving biologic therapeutics, including fusion proteins and antibodies, as well as cases relating to methods of treatment using the same. *Id.* In addition, Ms. Davis's familiarity with the subject matter at issue in this proceeding is demonstrated by her review of the '572 Patent, all cited prior art, and the IPR petition in this matter. Davis Decl. ¶ 10.

5. In her declaration, Ms. Davis also attests to her admission to practice s§42.10(c) and *Unified Patents, Inc. v. Parallel Iron, LLC*, IPR2013-00639, Paper 7 (PTAB Oct. 15, 2013). *See* Davis Decl. ¶¶ 1-10.

### **III. Conclusion**

For the foregoing reasons, Patent Owner respectfully request that the Board admit Kira A. Davis *pro hac vice* in this proceeding.

IPR2023-00884

Date: December 21, 2023

Respectfully Submitted,

By: /Adam R. Brausa/  
Adam R. Brausa, Reg. No. 60,287  
MORRISON & FOERSTER LLP  
425 Market Street  
San Francisco, California 94105  
Tel: (415) 268-6053  
[ABrausa@mofo.com](mailto:ABrausa@mofo.com)

*Counsel for Patent Owner*

**Certificate of Service (37 C.F.R. § 42.6(e)(4))**

I hereby certify that the attached PATENT OWNER'S MOTION FOR *PRO HAC VICE* ADMISSION OF KIRA A. DAVIS UNDER 37 C.F.R. § 42.10(c) and THE SUPPORTING DECLARATION OF KIRA A. DAVIS, were served on the date listed below via electronic mail upon the following counsel of record for Petitioner.

Raymond N. Nimrod (Reg. No. 31,987)  
Matthew A. Traupman (Reg. No. 50,832)  
Landon Andrew Smith (Reg. No. 79,248)  
QUINN EMANUEL URQUHART  
& SULLIVAN, LLP  
51 Madison Ave., 22nd Floor  
New York, NY 10010  
Email: [raynimrod@quinnemanuel.com](mailto:raynimrod@quinnemanuel.com)  
Email: [matthewtraupman@quinnemanuel.com](mailto:matthewtraupman@quinnemanuel.com)  
Email: [landonsmith@quinnemanuel.com](mailto:landonsmith@quinnemanuel.com)  
Email: [qe-samsungbioepis@quinnemanuel.com](mailto:qe-samsungbioepis@quinnemanuel.com)

Dated: December 21, 2023

/Adam R. Brausa/  
Adam R. Brausa, Reg. No. 60,287